Endocrine Abstracts

Background: We aimed to evaluate the added information provided by 68Ga-DOTATATE PET after two cycles of peptide receptor radionuclide therapy (PRRT) in patients with somatostatin receptor (SSTR)-expressing neuroendocrine tumors (NET).Methods: In this retrospective study, 105 patients (54 women and 51 men, 62.5&pm;10.5-year-old) with progressive NET treated with at least two cycles of 177Lu-DOTATATE were included. All patients had <...